CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 87 enrolled
Drug / intervention
Midodrine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02308124
NCT02308124Phase 4Completed
CompareCT.gov

Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study

Seoul National University Hospital·interventional·Posted Dec 4, 2014·Updated Oct 19, 2021

In Brief

A Phase 4 clinical trial evaluating Midodrine, Pyridostigmine Bromide, and 1 other intervention for Orthostatic; Hypotension, Neurogenic. Completed, enrolled 87 participants across 1 site.

Detailed Summary

Compare the effect of treatment of midodrine and pyridostigmine in neurogenic orthostatic hypotension and investigate the quality of life of treatment of neurogenic orthostatic hypotension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOrthostatic; Hypotension, Neurogenic
CountriesSouth Korea
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 4, 2014
Enrollment StartNov 1, 2014
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.6 years ago

Interventions

Midodrinedrug

Pyridostigmine Bromidedrug

Midodrine + pyridostigminedrug